Loading...
•
Mar 31
Moleculin Q1 2025 Earnings Report
Moleculin reported no revenue and a net loss in Q1 2025 while progressing its clinical development pipeline.
Key Takeaways
Moleculin Biotech reported a net loss of $6.4 million in Q1 2025 with no revenue, while continuing progress on its Annamycin trials for AML and STS lung metastases. Research and development expenses decreased year-over-year, and the company held $7.7 million in cash and equivalents as of quarter end.
No revenue was reported for Q1 2025.
Net loss totaled $6.4 million compared to $5.0 million in Q1 2024.
Cash and cash equivalents stood at $7.7 million at the end of Q1.
Enrollment continued in the pivotal Phase 3 MIRACLE trial for Annamycin.
Moleculin
Moleculin
Forward Guidance
Moleculin expects continued clinical advancement in 2025, with multiple data readouts planned, subject to securing additional financing.
Positive Outlook
- Enrollment and dosing in MIRACLE trial are underway.
- EMA approval expands the trial to 9 EU countries.
- Final data from the STS lung metastases trial expected by mid-2025.
- WP1066 trials progressing through external partnerships.
- Annamycin has multiple orphan drug designations and Fast Track Status.
Challenges Ahead
- No revenue generation in the quarter.
- Ongoing net losses highlight continued cash burn.
- Funding only supports operations into Q3 2025.
- Dependent on additional financing to sustain trials.
- Regulatory approvals for further trial phases still pending.